Colorectal Cancer in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2031

About GlobalData

List of Contents

List of Tables

List of Figures

1 Colorectal Cancer: Executive Summary

1.1 The colorectal cancer market will grow to $21.8B by 2031, at a compound annual growth rate of

3.3%

1.2 Combination therapies and immunotherapies for distinct segments are key R&D strategies in CRC

1.3 The level of unmet clinical need in colorectal cancer remains high during the forecast period, despite dramatic improvements by historical standards

1.4 The colorectal cancer pipeline is robust, with plenty of room for new market entrants

1.5 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.1.3 Classification and staging systems

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 Forecast methodology

4.4.1 Sources

4.4.2 Forecast assumptions and methods

4.4.3 Forecast assumptions and methods: diagnosed incident cases of CRC

4.4.4 Forecast assumptions and methods: diagnosed incident cases of CRC by AJCC stage at diagnosis

4.4.5 Forecast assumptions and methods: diagnosed incident cases of CRC by recurrence of stages I–III into stage IV disease

4.4.6 Forecast assumptions and methods: diagnosed incident cases of CRC by molecular markers

4.4.7 Forecast assumptions and methods: five-year diagnosed prevalent cases of CRC

4.5 Epidemiological forecast for CRC (2021–31)

4.5.1 Diagnosed incident cases of CRC

4.5.2 Age-specific diagnosed incident cases of CRC

4.5.3 Sex-specific diagnosed incident cases of CRC

4.5.4 Diagnosed incident cases of CRC by AJCC stage at diagnosis

4.5.5 Diagnosed incident cases of CRC by recurrence of stages I–III into

stage IV disease

4.5.6 Diagnosed incident cases of CRC by molecular markers

4.5.7 Five-year diagnosed prevalent cases of CRC

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact

4.6.3 Limitations of the analysis

4.6.4 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.2 KOL insights on disease management

5.2.1 US-specific KOL insights on disease management

5.2.2 5EU-specific KOL insights on disease management

5.2.3 Japan-specific KOL insights on disease management

5.2.4 China-specific KOL insights on disease management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Improving treatments for patients with KRAS/NRAS mutations

7.3 Improving treatment options in precision medicine

7.4 Overcoming resistance to EGFR- and VEGF-targeted therapies

7.5 Reduced age for routine disease screening

8 R&D Strategies

8.1 Overview of R&D strategies

8.1.1 Targeting MSS patients with immunotherapy

8.1.2 Combination Therapies

8.2 Clinical trials design

8.2.1 Increasing adoption of secondary quality of life endpoints

8.2.2 Increasing adoption of surrogate endpoints

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

12.5 China

12.5.1 Forecast

12.5.2 Key events

12.5.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary research – KOLs interviewed for this report

13.4.1 KOLs

13.5 Primary research – prescriber survey

13.6 About the authors

13.6.1 Analysts

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Epidemiology reviewers

13.6.5 Vice President of Disease Intelligence and Epidemiology”

Table 1: Colorectal cancer: key metrics in the 8MM

Table 2: 8MM, TNM staging and classification for CRC

Table 3: 8MM, Diagnosed incident cases of CRC by molecular markers, both sexes, ages ≥18 years, N, 2021

Table 4: CRC screening practices across the 8MM

Table 5: Treatment guidelines for CRC across the 8MM

Table 6: Current landscape of approved CRC agents in the 8MM

Table 7: Comparison of published clinical data for late-stage pipeline agents in CRC

Table 8: Top 10 completed deals by value, 2021-2023

Table 9: CRC market – global drivers and barriers, 2021-2031

Table 10: Key events impacting sales for CRC in the US, 2021-2031

Table 11: CRC market – drivers and barriers in the US, 2021-2031

Table 12: Key events impacting sales for CRC in the 5EU, 2021-2031

Table 13: CRC market – drivers and barriers in the 5EU, 2021-2031

Table 14: Key events impacting sales for CRC in Japan, 2021-2031

Table 15: CRC market – drivers and barriers in Japan, 2021-2031

Table 16: Key events impacting sales for CRC in China, 2021-2031

Table 17: CRC market – drivers and barriers in China, 2021-2031

Table 18: High-prescribing physicians (non-KOLs) surveyed, by country

Figure 1: Global sales forecast by country for CRC in 2021 and 2031

Figure 2: Analysis of the company portfolio gap in CRC during the forecast period

Figure 3: Competitive assessment of the marketed and pipeline drugs benchmarked against Braftovi, targeted therapy agents

Figure 4: Competitive assessment of the marketed and pipeline drugs benchmarked against Keytruda, immunotherapy agents

Figure 5: Risk factors associated with CRC

Figure 6: Tumor sites of the colon and rectum

Figure 7: 8MM, Diagnosed incidence of CRC, men, cases per 100,000 population, ages ≥18 years, 2011–31

Figure 8: 8MM, Diagnosed incidence of CRC, women, cases per 100,000 population, ages ≥18

years, 2011–31

Figure 9: 8MM, sources used and not used to forecast the diagnosed incident cases of CRC

Figure 10: 8MM, sources used to forecast the diagnosed incident cases of CRC by stage at diagnosis

Figure 11: 8MM, sources used to forecast the diagnosed incident cases of CRC by recurrence into stage IV disease

Figure 12: 8MM, sources used to forecast the diagnosed incident cases of CRC by molecular markers (KRAS mutation, NRAS mutation, BRAF mutation, BRAF V600E mutation, and PIK3CA/PTEN mutation)

Figure 13: 8MM, sources used to forecast the diagnosed incident cases of CRC by molecular markers (MSI-H/dMMR molecular subtype, HER2 amplification, MET amplification, and NTRK gene fusion)

Figure 14: 8MM, sources used to forecast the diagnosed incident cases of CRC by molecular markers (DPYD, high TMB, elevated CEA, and UGT1A1 mutation)

Figure 15: 8MM, sources used to forecast the diagnosed incident cases of CRC by molecular markers (POLE mutation, TP53 mutation, APC mutation, and PD-L1 expression on tumors)

Figure 16: 8MM, Sources used to forecast the five-year diagnosed prevalent cases of CRC

Figure 17: 8MM, Diagnosed incident cases of CRC, N, both sexes, ages ≥18 years, 2021

Figure 18: 8MM, Diagnosed incident cases of CRC by age, N, both sexes, 2021

Figure 19: 8MM, Diagnosed incident cases of CRC by sex, N, all ages, 2021

Figure 20: 8MM, Diagnosed incident cases of CRC by AJCC stage at diagnosis, N, all ages, 2021

Figure 21: 8MM, diagnosed incident cases of CRC by recurrence of stages I–III into stage IV

disease, N, both sexes, ages ≥18 years, 2021

Figure 22: 8MM, Five-year diagnosed prevalent cases of CRC, N, both sexes, ages ≥18 years, 2021

Figure 23: Treatment algorithm for localized CRC

Figure 24: Treatment algorithm for advanced/metastatic CRC

Figure 25: Unmet needs and opportunities in CRC

Figure 26: Overview of the ex-China development pipeline in CRC (Phase II–Phase III)

Figure 27: Key late-stage trials for targeted therapy CRC candidates that GlobalData expects to be approved in the 8MM during the forecast period

Figure 28: Key late-stage trials for immunotherapy CRC candidates that GlobalData expects to be approved in the 8MM during the forecast period

Figure 29: Competitive assessment of the marketed and pipeline drugs benchmarked against Braftovi, targeted therapy agents

Figure 30: Competitive assessment of the marketed and pipeline drugs benchmarked against Keytruda, immunotherapy agents

Figure 31: Analysis of the company portfolio gap in CRC during the forecast period

Figure 32: Global (8MM) sales forecast by country for CRC in 2021 and 2031

Figure 33: Sales forecast by class for CRC in the US in 2021 and 2031

Figure 34: Sales forecast by class for CRC in the 5EU in 2021 and 2031

Figure 35: Sales forecast by class for CRC in Japan in 2021 and 2031

Figure 36: Sales forecast by class for CRC in China in 2021 and 2033